Training of patients for self-management of oral anticoagulant therapy: Standards, patient suitability, and clinical aspects

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 1, 1999, Pages 109-116

  Mörsdorf, Stefan ^a,d   Erdlenbruch, Wolfhardt ^a   Taborski, Uwe ^b   Schenk, Joachim F ^a   Erdlenbruch, Karin ^a   Novotny Reichert, Gerhard ^c   Krischek, Boris ^e   Wenzel, Ernst ^a  

^a University Clinics   (Germany)

^b Kerckhoffklinik   (Germany)

^c Abt f Kardiologie   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e NONE

Author keywords

Home monitoring; INR; Oral anticoagulants; Patient training; Self management

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG INDICATION; DRUG SELF ADMINISTRATION; FEMALE; FINANCIAL MANAGEMENT; HOME MONITORING; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; MALE; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; STANDARDIZATION; VENOUS BLOOD;

EID: 0032930901     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996433     Document Type: Article

References (36)

1. 1. Harrington R, Ansell J. Risk-benefit assessment of anticoagulant therapy. Drug Safety 1991;6:54-69
2. 2. van den Besselaar AM, Breddin K, Lutze G, et al. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coag Fibrinolysis 1995;6:726-732
3. 3. Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med 1993; 153:1441-1447
4. 4. Ostermann H. Indikationen und Probleme langfristiger medikamentöser Gerinnungshemmung. Internist 1997;38:672-679
5. 5. Schulman S. Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group. J Intern Med 1994;236:143-152
6. 6. Riva G, Straub PW, Vorburger C, Uehlinger A. Orale Antikoagulation, Qualitätskontrolle und Standardisierung der Prothrombinzeitbestimmung. Schweiz Med Wochenschr 1976;106:809-812
7. 7. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428
8. 8. van der Meer FJ, Briet E, Vandenbroucke JP, et al. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997;98:893-900
9. 9. White RH, Becker DM, Gunther Maher MG. Outpatient use of a portable international normalized ratio/prothrombin time monitor. South Med J 1994:87:206-210
10. 10. Horstkotte D, Hohnloser S, Keller F, et al. Empfehlung zur Einführung der Internationalen Normalisierten Ratio (INR) als objektives Mass für die Intensität einer oralen Antikoagulantien-Therapie. Z Kardiol 1994;83:676-679
11. 11. Horstkotte D, Piper C, Wiemer M, Schulte HD, Schultheiss HP. Optimization of oral anticoagulation following heart valve replacement: Results of randomized prospective studies. Ann Hematol 1996;72(Suppl. 1)(Abst):A90
12. 12. Bernardo A. Gerinnungsselbstkontrolle durch den Patienten. Med Monatsschr Pharm 1997;20:30-35
13. 13. Körtke H, Breymann T, Minami K, et al. Früher Beginn der Quickwert-Selbstbestimmung durch den Patienten nach mechanischem Herzklappenersatz. 2. Gemeinsame. Jahrestagung der Gesellschaft für Thorax-, Herz-ud Gefässchirurgie Österreichs, Deutschlands und der Schweiz, Wien, 1996. Thorac Cardiovasc Surg 1996;44:32
14. 14. Azar AJ, Deckers JW, Rosendaal FR, et al. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemostas 1994;72: 347-351
15. 15. McCormack PM, Stinson JC, Hemeryck L, Feely J. Audit of an anticoagulant clinic: Doctor and patient knowledge. Ir Med J 1997;90:192-193
16. 16. Bernardo A, Taborski U, Wittstamm FJ. Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation: Standards und Informationen, Bad Nauheim, Selbstverlag; 1996
17. 17. Ansell JE, Hughes R. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996; 132:1095-1100
18. 18. Ansell JE, Patel N, Ostrovsky D, et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995; 155:2185-2189
19. 19. Bernardo A, Halhuber C. Die Quickwert-Selbstbestimmung, Stuttgart, Trias Verlag; 1995
20. 20. Bernardo A, Schüpphaus S, Taborski U, Wittstamm FJ. Die Selbstkontrolle der oralen Antikoagulation. Dtsch Ärzteblatt 1995; 92:A442-A444
21. 21. Kapiotis S, Quehenberger P. Speiser W. Evaluation of the new method Coaguchek for the determination of prothrombin time from capillary blood: Comparison with Thrombotest on KC-1. Thromb Res 1995;77:563-567
22. 22. Seamark DA, Backhouse S, Barber P, et al. Validation of current practice and a near patient testing method for oral-anticoagulant control in general practice. J R Soc Med 1997;90:657-660
23. 23. Taborski U, Schüpphaus S, Böker C, et al. Vergleich PT-Sofortbestimmung mit konventioneller Labormethode an drei Zentren. Ann Hematol 1992;64(Abst):A18
24. 24. Taborski U, Heidinger K, Müller-Berghaus G. Imprecision of INR self-testing compared to laboratory testing. Ann Hematol 1998;76(Suppl. 1)(Abst):A100
25. 25. Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalised ratio (INR) using a portable whole blood monitor. Thromb Res 1997;85:77-82
26. 26. Ansell J, Holden A, Knapic N. Patient self-management of oral anticoagulalion guided by capillary (fingerstick) whole blood prothrombin times. Arch Intern Med 1989;149:2509-2511
27. 27. Seyfert UT, Sorg L, Wenzel E. The determination of the prothrombin time in capillary blood using a thromboplastin based on recombinant tissue factor and synthetic phospholipids. Clin Lab 1994;8:1-10
28. 28. Massicotte P, Murzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr 1995;127:389-394
29. 29. Stone S, Holden A, Knapic N, Ansell J. Comparison between videotape and personalized patient education for anticoagulant therapy. J Fam Pract 1989;29:55-57
30. 30. Hoffmann E. Selbstkontrolle der oralen Antikoagulation. Dtsch Ärzteblatt 1996;93:A1322-A1324
31. 31. White RH, McCurdy SA, von Marensdorff H, Woodruff DEJ, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med 1989;111:730-737
32. 32. Wittstamm FJ, Benesch L. Sicheres Quickwert-Management durch Selbstbestimmung. Z Kardiol 1992;81:176-179
33. 33. Hasenkam JM, Kimose HH, Knudsen L, et al. Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997;11:935-942
34. 34. Lancaster TR, Singer DE, Sheehan MA, et al. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991;151:1944-1949
35. 35. Koefeld BG, Gullov AL, Petersen P. Atrial fibrillation and apoplexy - risk and prevention. Nord Med 1996;111:171-175
36. 36. Meier B. Blood thinning in heart patients. Ther Umschau 1995; 52:661-671